Drugmaker Insmed Inc said it on Wednesday it had bought the rights to an experimental early-stage respiratory drug from Britain's AstraZeneca Plc in a deal worth $150 million.
AstraZeneca will get $30 million in upfront fees and $120 million in various milestone payments, Insmed said.
07:16 Aroldis Chapman Acquired by Yankees in Five-Year, $86 Million Deal15
07:16 Aroldis Chapman, Yankees agree to five-year, $86 million record deal15
06:10 Sources: Carlos Gomez, Rangers agree on 1-year, $11.5 million deal23
22:35 Bryce Harper's request for record $400 million deal too much for Nationals: report9